Advertisement

Journal of Endocrinological Investigation

, Volume 42, Issue 12, pp 1443–1450 | Cite as

Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors

  • I. MazaricoEmail author
  • I. Capel
  • O. Giménez-Palop
  • L. Albert
  • I. Berges
  • F. Luchtenberg
  • Y. García
  • L. A. Fernández-Morales
  • V. J. De Pedro
  • A. Caixàs
  • M. Rigla
Original Article

Abstract

Introduction

Immune checkpoint inhibitors (ICI), such as programmed death-1 inhibitors (anti-PD1), have become a cornerstone for the treatment of different advanced cancers. These antibodies act as modulators of immune checkpoint proteins. However, ICI can lead to the breaking of immune self-tolerance, inducing autoimmune side effects (irAEs), including endocrinopathies. One of the most frequent endocrine irAE of anti-PD1 is thyroid dysfunction, but the exact mechanism of this disease still remains unknown.

Materials and methods

We conducted a descriptive retrospective study, analyzing 11 patients who received at least one dose of anti-PD1 (nivolumab or pembrolizumab) and presented thyroid irAEs. Data were collected between September 2015 and May 2018 in our hospital. The aim was to analyze the clinically relevant features of thyroid irAEs and the frequency of antithyroid antibodies (ATA) positivity observed on them.

Results and discussion

8 of the 11 patients were treated with nivolumab and the other three patients received pembrolizumab. Six patients presented silent thyroiditis with a thyrotoxicosis phase; three patients developed directly primary/subclinical hypothyroidism and two patients showed primary hyperthyroidism. Thyroid autoantibodies (anti-Thyroglobulin and anti-Thyroid Peroxidase) were assessed in all the 11 patients, and only in two of them (18%) a positive titer was displayed. Anti-TSH receptor antibodies (TRAbs) were examined in five patients, three with painless thyroiditis at the time of thyrotoxicosis and two with primary hyperthyroidism, and they all had undetectable levels.

Conclusions

In our sample of 11 Caucasian patients with thyroid dysfunction related with anti-PD1, we found low frequency of ATA positive titers, comparable to other recent reports in others ethnicities, which could suggest that silent thyroiditis due to pembrolizumab or nivolumab has a different pathogenesis from the classical autoimmune spontaneous thyroiditis. Further investigations are required to completely understand the immune mechanisms involved.

Keywords

Immune checkpoint inhibitors Endocrine adverse events Thyroid dysfunctions Cancer immunotherapy Thyroiditis Nivolumab 

Notes

Funding

This article did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Compliance with ethical standards

Conflict of interest

The authors declare that there is no conflict of interest that could prejudice the impartiality of the article.

Ethical approval

All procedures performed were in accordance with the ethical standards of the institution and with the 1964 Helsinki Declaration and its later amendments.

Informed consent

Informed consent is not required.

References

  1. 1.
    Chalan P, Di Dalmazi G, Pani F, De Remigis A, Corsello A, Caturegli P (2018) Thyroid dysfunctions secondary to cancer immunotherapy. J Endocrinol Invest 41(6):625–638.  https://doi.org/10.1007/s40618-017-0778-8 CrossRefPubMedGoogle Scholar
  2. 2.
    Cukier P, Santini FC, Scaranti M, Hoff AO (2017) Endocrine side effects of cancer immunotherapy. Endocr Relat Cancer 24(12):T331–T347.  https://doi.org/10.1530/ERC-17-0358 CrossRefPubMedGoogle Scholar
  3. 3.
    Haanen JBAG, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol 28(suppl_4):iv119–iv142.  https://doi.org/10.1093/annonc/mdx225 CrossRefPubMedGoogle Scholar
  4. 4.
    Ruggeri RM, Campennì A, Giuffrida G et al (2018) Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know). J Endocrinol Invest.  https://doi.org/10.1007/s40618-018-0984-z CrossRefPubMedGoogle Scholar
  5. 5.
    June CH, Warshauer JT, Bluestone JA (2017) Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat Med 23(5):540–547.  https://doi.org/10.1038/nm.4321 CrossRefPubMedGoogle Scholar
  6. 6.
    Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F (2013) Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 98(4):1361–1375.  https://doi.org/10.1210/jc.2012-4075 CrossRefPubMedGoogle Scholar
  7. 7.
    Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB (2017) Current diagnosis and management of immune related adverse events (irAEs) Induced by immune checkpoint inhibitor therapy. Front Pharmacol 8:49.  https://doi.org/10.3389/fphar.2017.00049 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Eigentler TK, Hassel JC, Berking C et al (2016) Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 45:7–18.  https://doi.org/10.1016/j.ctrv.2016.02.003 CrossRefPubMedGoogle Scholar
  9. 9.
    Guaraldi F, La Selva R, Samà MT et al (2018) Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution. J Endocrinol Invest 41(5):549–556.  https://doi.org/10.1007/s40618-017-0772-1 CrossRefPubMedGoogle Scholar
  10. 10.
    Delivanis DA, Gustafson MP, Bornschlegl S et al (2017) Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab 102(8):2770–2780.  https://doi.org/10.1210/jc.2017-00448 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Osorio JC, Ni A, Chaft JE et al (2017) Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol. 28(3):583–589.  https://doi.org/10.1093/annonc/mdw640 CrossRefGoogle Scholar
  12. 12.
    Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23–34.  https://doi.org/10.1056/NEJMoa1504030 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Koh LKH, Greenspan FS, Yeo PPB (2009) Interferon-α induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 7(6):891–896.  https://doi.org/10.1089/thy.1997.7.891 CrossRefGoogle Scholar
  14. 14.
    Vassilopoulou-Sellin R, Sella A, Dexeus FH, Theriault RL, Pololoff DA (1992) Acute thyroid dysfunction (thyroiditis) after therapy with interleukin-2. Horm Metab Res 24(9):434–438.  https://doi.org/10.1055/s-2007-1003353 CrossRefPubMedGoogle Scholar
  15. 15.
    Kobayashi T, Iwama S, Yasuda Y et al (2018) Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study. J Endocr Soc 2(3):241–251.  https://doi.org/10.1210/js.2017-00432 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Yano S, Ashida K, Nagata H et al (2018) Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma. BMC Endocr Disord 18:36.  https://doi.org/10.1186/s12902-018-0267-x CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Iadarola C, Croce L, Quaquarini E et al (2019) Nivolumab induced thyroid dysfunction: unusual clinical presentation and challenging diagnosis. Front Endocr (Lausanne).  https://doi.org/10.3389/fendo.2018.00813 CrossRefGoogle Scholar
  18. 18.
    Alhusseini M, Samantray J (2017) Hypothyroidism in cancer patients on immune checkpoint inhibitors with anti-PD1 agents: insights on underlying mechanisms. Exp Clin Endocrinol Diabetes 125(4):267–269.  https://doi.org/10.1055/s-0042-119528 CrossRefPubMedGoogle Scholar
  19. 19.
    de Filette J, Jansen Y, Schreuer M et al (2016) Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab 101(11):4431–4439.  https://doi.org/10.1210/jc.2016-2300 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Orlov S, Salari F, Kashat L, Walfish PG (2015) Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J Clin Endocrinol Metab.  https://doi.org/10.1210/jc.2014-4560 CrossRefPubMedGoogle Scholar
  21. 21.
    Morganstein DL, Lai Z, Spain L et al (2017) Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf) 86(4):614–620.  https://doi.org/10.1111/cen.13297 CrossRefGoogle Scholar
  22. 22.
    Dulos J, Carven GJ, van Boxtel SJ et al (2012) PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother 35(2):169–178.  https://doi.org/10.1097/CJI.0b013e318247a4e7 CrossRefPubMedGoogle Scholar
  23. 23.
    Rotondi M, Coperchini F, Magri F, Chiovato L (2014) Serum-negative autoimmune thyroiditis: what’s in a name? J Endocrinol Invest 37(6):589–591.  https://doi.org/10.1007/s40618-014-0083-8 CrossRefPubMedGoogle Scholar
  24. 24.
    Angell TE, Min L, Wieczorek TJ, Hodi FS (2018) Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma HHS public access. Genes Dis 5(1):46–48.  https://doi.org/10.1016/j.gendis.2017.11.002 CrossRefPubMedGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2019

Authors and Affiliations

  • I. Mazarico
    • 1
    Email author
  • I. Capel
    • 1
  • O. Giménez-Palop
    • 1
  • L. Albert
    • 1
  • I. Berges
    • 1
  • F. Luchtenberg
    • 1
  • Y. García
    • 2
  • L. A. Fernández-Morales
    • 2
  • V. J. De Pedro
    • 3
  • A. Caixàs
    • 1
  • M. Rigla
    • 1
  1. 1.Endocrinology and Nutrition Department, Parc Taulí University HospitalInstitut d’Investigació i Innovació ParcTaulí (I3PT), UABSabadellSpain
  2. 2.Oncology Department. Parc, Taulí University HospitalInstitut d’Investigació i Innovació ParcTaulí (I3PT), UABSabadellSpain
  3. 3.Pharmacy Department. Parc, Taulí University HospitalInstitut d’Investigació i Innovació ParcTaulí (I3PT), UABSabadellSpain

Personalised recommendations